Want to see XXII full AI Analyst Report?
XXII Stock Chart & Stats
$0.76
-$0.08(-1.39%)
At close: 4:00 PM EST
$0.76
-$0.08(-1.39%)
Day’s Range― - ―
52-Week Range$3.74 - $1,359.00
Previous CloseN/A
Volume40.32K
Average Volume (3M)2.49M
Market Cap
$1.49M
Enterprise Value-$6.91
Total Cash (Recent Filing)$9.54M
Total Debt (Recent Filing)$1.32M
Price to Earnings (P/E)―
Beta2.19
Next Earnings
Aug 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-214.80
Shares Outstanding345,124
10 Day Avg. Volume328,967
30 Day Avg. Volume2,485,312
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)2.70
Price to Sales (P/S)6.03
P/FCF Ratio-4.95
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-18
Revenue Forecast (FY)$32.50M
Bulls Say, Bears Say
Bulls Say
Regulatory / Scientific ValidationHaving the only FDA-authorized reduced‑nicotine cigarette creates a structural competitive moat: regulatory endorsement plus scientific recognition supports differentiated positioning, eases market access, and underpins long-term product credibility versus incumbents and new entrants.
Improved Leverage And Balance SheetMaterial reduction in leverage and positive equity materially improves financial resilience. Low debt lowers default risk and preserves borrowing capacity, enabling the company to fund commercial rollout and marketing investments without excessive interest burden or immediate refinancing pressure.
Retail Distribution Traction And Execution PlanMeaningful retail wins and a clear rollout target provide a durable avenue to scale revenue and improve product availability. Expanded outlet coverage and hiring for marketing/sales support network effects that can sustainably raise demand and improve unit economics over the medium term.
Bears Say
Negative Cash Flow / Cash BurnPersistent negative operating and free cash flow means the company consumes balance sheet resources to operate. Over months this forces reliance on external financing or asset dispositions, constraining strategic investments and increasing dilution or refinancing risk if cash burn persists during commercialization.
Negative Gross Profit And Operating LossesOngoing negative gross margins indicate underlying unit economics are unfavorable or pricing/mix remains weak. Even with revenue growth, failure to achieve positive gross profit undermines pathway to sustainable operating profits and suggests structural margin issues that scaling alone may not resolve.
Contract Manufacturing Termination RiskLoss of a manufacturing customer reduces capacity utilization and predictable revenue, raising operational and margin pressure. Replacing that volume may be difficult, and lower utilization can increase per‑unit costs, weakening the economics of both contract manufacturing and the company's own product lines.
22nd Century News
XXII FAQ
What was 22nd Century’s price range in the past 12 months?
22nd Century lowest stock price was $3.74 and its highest was $1359.00 in the past 12 months.
What is 22nd Century’s market cap?
22nd Century’s market cap is $1.49M.
When is 22nd Century’s upcoming earnings report date?
22nd Century’s upcoming earnings report date is Aug 19, 2026 which is in 30 days.
How were 22nd Century’s earnings last quarter?
22nd Century released its earnings results on May 07, 2026. The company reported -$101.4 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is 22nd Century overvalued?
According to Wall Street analysts 22nd Century’s price is currently Overvalued.
Does 22nd Century pay dividends?
22nd Century does not currently pay dividends.
What is 22nd Century’s EPS estimate?
22nd Century’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does 22nd Century have?
22nd Century has 345,124 shares outstanding.
What happened to 22nd Century’s price movement after its last earnings report?
22nd Century reported an EPS of -$101.4 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -16.344%.
Which hedge fund is a major shareholder of 22nd Century?
Currently, no hedge funds are holding shares in XXII
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
22nd Century
22nd Century Group, Inc. is an agricultural biotechnology firm dedicated to mitigating the risks associated with tobacco use and improving health and wellness through advanced plant science. The company serves the life science and consumer product sectors. Its innovations include ultra-low nicotine tobacco and cigarette offerings, marketed under the VLN King and VLN Menthol King brands, as well as SPECTRUM research cigarettes used in independent scientific investigations. Furthermore, 22nd Century Group collaborates with Keygene N.V. to cultivate hemp and cannabis plants engineered for superior cannabinoid content and enhanced agricultural characteristics, intended for medical, therapeutic, farming, and other applications. Established in 1998, the company is based in Buffalo, New York.
Technical Analysis
Universal
―
Turning Point Brands
―
Greenlane Holdings
―
Kaival Brands Innovations Group
―
Ispire Technology, Inc.
―
Ownership Overview
73.39% Insiders
1.35% Mutual Funds
― Other Institutional Investors
25.26% Public Companies and
Individual Investors